Splenectomy for refractory thrombocytopenia in juvenile systemic lupus erythematosus by Campos, LMA et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Pediatric Rheumatology
Open Access Poster presentation
Splenectomy for refractory thrombocytopenia in juvenile systemic 
lupus erythematosus
LMA Campos*, FJ Fiorot and CAA Silva
Address: Instituto da Criança – Clinical Hospital, University of São Paulo, São Paulo/SP, Brazil
* Corresponding author    
Background
The prevalence of autoimmune thrombocytopenia in
juvenile systemic lupus erythematosus (JSLE) ranges from
7–52% (mean 14,5%) but profound rates (<50,000/mL)
are uncommon. Although the exact mechanism is
unknown, the spleen has been implicated either as the
source of antiplatelet antibodies or the site of sensitized
platelets destruction. Splenectomy is rarely indicated due
to the increased risk of severe infections and controversial
effectiveness.
Materials and methods
From 1983 to 2007, 5079 patients were followed at the
Pediatric Rheumatology Unit and JSLE occurred in 228
(4.5%). We report three female JSLE patients with refrac-
tory thrombocytopenia to whom splenectomy was indi-
cated.
Results
Data are described in table 1. Thrombocytopenia pre-
ceded JSLE diagnosis in a mean of 30 months. All patients
had initial normal bone marrow and positive antiphos-
pholipid antibodies.
Conclusion
Splenectomy should be considered for the treatment of
thrombocytopenia refractory cases. Results are variable.
Bone marrow hypoplasia should be excluded.
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Table 1: Clinical and laboratorial manifestations and treatment of refractory thrombocytopenia
Patient SSR ACS MJS
Age (years) 16 12 12
Months between JSLE/splenectomy 1 38 10
Previous treatment Pd, MP, CYC Pd, MP, HCQ, IVG, AZA, C, RTX Pd, MP, HCQ, IVG, AZA, C, MMF, RTX
Platelet count 3,000/mL 7,000/mL 10,000/mL
Splenectomy Held Held Indicated (cancelled due to bone marrow hypoplasia-
toxicity?)
Platelet count (time after surgery) 107,000/mL (2 w)
469,000/mL (2 m)
140,000/mL (1 d)
396,000/mL (3 d)
-
Recurrences none 1 month after -
Pd = prednisone; MP = Methylprednisolone pulse; CYC = Cyclophosphamide; HCQ = Hydroxychloroquine; IVG = Gammaglobulin; AZA = 
Azathioprine; C = Cyclosporine; MMF = mycophenolate mofetil; RTX = Rituximab